Cellnovo Group announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero’s Artificial Pancreas (AP) technology into Cellnovo’s mobile diabetes management systems.
The non-exclusive worldwide agreement allows Cellnovo to commercialize a Cellnovo-TypeZero product in the future. Integration efforts are currently underway with a product launch expected in 2018. No financial terms have been disclosed.
TypeZero’s AP software, known as inControl AP, will be incorporated directly into Cellnovo’s Bluetooth-enabled micropump. inControl AP continuously monitors blood glucose levels via a smartphone application and automatically delivers corrections to regulate blood sugar levels through an integrated insulin pump.
“Our partnership with TypeZero brings us another step closer to delivering one of the first end-to-end diabetes management systems,” said Sophie Baratte, Chief Executive Officer of Cellnovo. “We are confident that this strategic collaboration will result in a sophisticated product that improves the quality of life for patients with type 1 diabetes.”
“The future of diabetes care is rapidly progressing toward integrated solutions that simplify the device burden that people with type 1 diabetes face,” said Chad Rogers, Chief Executive Officer of TypeZero. “The Cellnovo mobile diabetes management system is an ideal platform for artificial pancreas system development because of its real-time connected data and discreetness to suit the needs and lifestyle of patients. I believe the combination of our artificial pancreas technology with Cellnovo’s advanced pump system can fundamentally shift the way we treat type 1 diabetes, and we’re excited about that possibility.”
